Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 19 briefings matching “diabetes”

Reset all filters

Endocrinology

Endocrinology Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

ENDOCRINOLOGY · REAL-WORLD COHORT

Metformin-supportive nutrition: When gut microbes eat drugs

Zhao et al. identify microbial AdhE as a metformin-degrading enzyme in metformin low-responders and propose enzyme-based microbiome intervention as a strategy to rescue therapy. Published in Cell metabolism, these peer-reviewed endocrinology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readCell MetabolismNov 3, 2026

ENDOCRINOLOGY · CLINICAL PRACTICE

Ozempic in Pregnancy: Diabetes, Not Drug, Linked to Early Births?

The reason you're taking Ozempic or Wegovy matters during pregnancy, with underlying diabetes potentially posing a greater risk than the medication itself. This study challenges the previously held, often generalized, assumption that GLP-1 medications alone are responsible for pregnancy complications.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 13, 2026

ENDOCRINOLOGY · REAL-WORLD COHORT

Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With New-Onset (Stage 3) Type 1 Diabetes

Teplizumab-specific recommendations are identified, with broader principles framed for adaptation across health systems. This article addresses who should lead care, how to approach eligibility and timing, how to assess β-cell reserve and infection risk, how to sequence treatment with diabetic ketoacidosis recovery and early education, and how to monitor treatment safely.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readDiabetes CareNov 11, 2026

ENDOCRINOLOGY · REAL-WORLD COHORT

Transient Cognitive Vulnerability After Hypoglycemia in Adults With Type 1 Diabetes: Evidence From Continuous Glucose Monitoring and Cognitive Ecologic Momentary Assessment

Hypoglycemia was associated with a transient period of cognitive vulnerability largely confined to the hour after an event, with little evidence of delayed effects. Findings support avoiding or exercising caution during cognitively demanding tasks for up to an hour after a hypoglycemic event.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readDiabetes CareNov 10, 2026

ENDOCRINOLOGY · RANDOMIZED CLINICAL TRIAL

Common Genetic Variants Near SLC2A2 and Glycemic Response to Glimepiride in the GRADE Comparative Effectiveness Clinical Trial

Genetic variation influences glycemic response to glucose-lowering medications, with SLC2A2 emerging as a genetic factor that modulates sulfonylurea response. These findings warrant further study to evaluate whether low-response allele carriers would benefit from alternative glucose-lowering therapies to advance precision diabetes care.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readDiabetes CareNov 5, 2026

ENDOCRINOLOGY · REAL-WORLD COHORT

Presentation, management, and outcomes of ectopic Cushing syndrome: an international, multicentre, retrospective, cohort study

Outcomes in ectopic Cushing syndrome are driven by early control of hypercortisolism. Failure to achieve remission within 6 months is associated with markedly worse complications and risk of death, supporting ectopic Cushing syndrome as a time-critical endocrine emergency.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet Diabetes & EndocrinologyNov 3, 2026

ENDOCRINOLOGY · REAL-WORLD COHORT

Longitudinal Changes in Exocrine Biomarkers in Children at Risk of Type 1 Diabetes in the ENDIA Study

Changes in exocrine biomarkers were detectable early in the natural history of type 1 diabetes, with a delayed rise of FE-1 in infants who later progressed to multiple islet autoantibodies or type 1 diabetes and a decrease in IRT following islet autoantibody seroconversion. The exocrine pancreas is increasingly implicated in type 1 diabetes.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readDiabetes CareNov 2, 2026

ENDOCRINOLOGY · REAL-WORLD COHORT

Clinical and metabolic subtypes of recent-onset adult type 1 diabetes: a prospective cohort study

Our results indicate that individuals with combined autoimmunity and lower insulin sensitivity present with clinical diabetes earlier than classic type 1 diabetes along the β-cell decline trajectory, identifying a potential timeframe for disease-modifying interventions in specific type 1 diabetes subtypes. Adult-onset type 1 diabetes exhibits substantial heterogeneity.

4/5 Strong Trial

Evidence Meter · 4/5

Strong Clinical Evidence

Tested directly in patients through a prospective clinical trial or large multicenter human cohort.

1 min readThe Lancet Diabetes & EndocrinologyOct 30, 2026

ENDOCRINOLOGY · PHASE III

Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial

In Japanese adults with obesity disease, once-daily orforglipron resulted in statistically superior reductions in bodyweight versus placebo (inactive comparison treatment), with a safety profile consistent with that of other GLP-1 receptor agonists. Orforglipron, a small-molecule, non-peptide, oral GLP-1 receptor agonist, has shown bodyweight reduction and cardiometabolic benefits in adults with obesity across Phase 3 trials globally.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Diabetes & EndocrinologyOct 30, 2026

ENDOCRINOLOGY · REAL-WORLD COHORT

Reactions to Race[ism]: The Relationship Between Differential Treatment Based on Race and Diagnosed Diabetes Status in U.S. Adults

Experiences of racial discrimination were common among U.S. adults and were reported more frequently by adults with diabetes. Because discrimination can contribute to chronic stress, reduced access to high-quality care, and barriers to diabetes self-management, consideration of racism-related exposures is important in efforts to understand and address diabetes disparities.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readDiabetes CareOct 29, 2026

ENDOCRINOLOGY · PHASE I/II

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity

In adults with T1D and overweight/obesity, acmopatide was associated with improved glycemic control and clinically meaningful weight loss without DKA or severe hypoglycemia events. To evaluate the efficacy (real-world effectiveness in the trial) and safety of acmopatide, a signal-biased glucagon-like peptide 1/glucose-dependent insulinotropic polypeptide receptor agonist, in adults with type 1 diabetes (T1D) and overweight/obesity.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readDiabetes CareOct 28, 2026

ENDOCRINOLOGY · GUIDELINE / OPINION

The development of obesity pharmacotherapy: from early challenges and setbacks to recognition by WHO

We take a critical historical perspective, charting the highs and lows of obesity medication development and examining the scientific, regulatory, and societal factors that have slowed or impeded the translation of pharmacological advances into safe, effective, and widely accepted treatments for obesity. Reflecting this paradigm shift, WHO issued global guidelines and included GLP-1 receptor agonists in the Essential Medicines List, albeit for a narrowly defined population.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet Diabetes & EndocrinologyOct 19, 2026

Showing 12 of 19 medical briefings

Interactive Fact Check